We are proud to announce that Eagle IP has been ranked once more in Tier 1 (the highest tier) for Patent Prosecution in the IP Stars 2026 Patent Firms Ranking by Managing IP. The rankings cover over 70 jurisdictions worldwide and recognize the top recommended firms for patent filing, prosecution, and disputes work. This Tier 1 placement is a testament to the positive feedback our clients have provided to Managing IP during their annual reviews.

It is with great pride that we have been included in this highest category among just a select few top firms in Hong Kong. We are deeply grateful to Managing IP for this recognition of our work. At Eagle IP, we are dedicated to providing exceptional service to our clients by drawing upon our hands-on knowledge of US and Chinese patent law, our proven ability to craft sophisticated and creative patent strategies, and our strong technical expertise. We will continue to build upon these strengths to deliver the highest level of service and support to the innovators who entrust us with protecting their groundbreaking ideas.

As always, a huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

我們過去活動

Recommended Insights

Narrow Claim Scope of a Chinese Utility Model Patent Fuels Design-Arounds by Failing to Curb Competing Products:

2020年10月28日
Learning from a 2019 China’s Top 50 Representative IP Case The number of patent applications in China is now the highest in the world, with more than half the applications filed as utility model applications (UMs). For example, there were more than 2 million UMs filed in 2018 alone (for the difference between a utility […]

China Releases Draft Implementation Guidelines for the Drug Administration Law

2022年6月2日
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]

Patent Inventiveness in China: Why “Common Knowledge” Must Be Proven, Not Assumed

2026年8月14日
A Case Study of the "Electronic Blackboard" Case, (2025) SPC Zhi Xing Zhong No. 286 I. Introduction In assessing inventive step for invention patents, determining whether a technical solution would have been “readily conceivable” to a person skilled in the art has long been one of the most disputed and uncertain aspects of the analysis. […]

How a Secondhand Ground Brush Wiped Away a Chinese Patent

2024年12月4日
A Chinese robot vacuum company digs up “hidden evidence” to successfully invalidate a patent owned by its biggest competitor.  Highlights Background  With the growth of online shopping, it is easier than ever to provide evidence of a sale when the product is still being sold on the market. But what if the product is no […]
Top crossarrow-right